Moreover, the functional capacity (ability to form a colony in CFC assay) of surviving normal CD34+ cells was unaffected by either drug alone or combination (Figure 5B) whereas for CML-CP cells there were16 times fewer total CFC with the combination treatment compared to normal; average 4% (CML) versus 64% (normal) of respective NDC. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.